Targeting mTOR signaling in lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• Lung cancer is the leading cause of cancer mortality worldwide, with current treatments showing limitations.
• Improved therapeutic strategies are crucial for enhancing patient survival and quality of life.
• Intracellular signaling pathways, including Ras/Raf/Erk and PI3K/Akt, are critical in cancer development.

Purpose of the Study:

• To review the molecular underpinnings of the PI3K/Akt/mTOR signaling pathway in lung cancer.
• To discuss the therapeutic potential of targeting this pathway, particularly with mTOR inhibitors.
• To explore multi-targeted strategies for improved lung cancer treatment.

Main Methods:

• Review of existing literature on PI3K/Akt/mTOR signaling in lung cancer.
• Analysis of pre-clinical and clinical studies on mTOR inhibitors.
• Discussion of receptor tyrosine kinases (RTKs) and downstream signaling mediators.

Main Results:

• The PI3K/Akt/mTOR pathway is frequently dysregulated in lung cancer.
• mTOR inhibitors have shown promise in other cancers but have not yet been successful in lung cancer.
• Multi-targeted strategies may offer a more effective approach.

Conclusions:

• Understanding PI3K/Akt/mTOR signaling is vital for developing novel lung cancer therapies.
• Further research into mTOR inhibitors and combination therapies is warranted.
• Targeting this pathway holds potential for improving outcomes in lung cancer patients.